Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Palo Alto, California 94303


Purpose:

To provide ganciclovir on a compassionate use basis to immunocompromised patients with serious cytomegalovirus (CMV) infections and to study safety and efficacy in this patient population.


Criteria:

Inclusion Criteria Concurrent Medication: Allowed: - Topical acyclovir. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: - Mild to moderate cytomegalovirus (CMV) infections that fail to satisfy the clinical severity criteria. - Transplant where a trial reduction of immunosuppressive drug treatment is not feasible. - Congenital or neonatal CMV infections where there is not documented congenital or acquired immunodeficiency. - Neutropenia unless it is pre-existing. - Thrombocytopenia unless it is pre-existing. Concurrent Medication: Excluded: - Other myelosuppressive drugs such as cancer chemotherapy agents, interferon, foscarnet, or nucleoside analogs. Patients with the following are excluded: - Mild to moderate cytomegalovirus (CMV) infections that fail to satisfy the clinical severity criteria. - Transplant where a trial reduction of immunosuppressive drug treatment is not feasible. - Congenital or neonatal CMV infections where there is not documented congenital or acquired immunodeficiency. - Neutropenia unless it is pre-existing. - Thrombocytopenia unless it is pre-existing. Patients must be immunocompromised with a serious cytomegalovirus (CMV) infection. This would include pneumonia, gastrointestinal disease, hepatitis, or other organ-specific disease or severe wasting syndrome. Patients with pre-existing neutropenia or thrombocytopenia, and immediate life-threatening disease can be included if the investigator believes that delay in starting ganciclovir therapy is not advisable. In such patients, the investigator must advise the patient of the risk of further marrow suppression and the increased risk of infection or bleeding; and the patient must sign an amended informed consent form.


NCT ID:

NCT00002024


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Palo Alto, California 94303
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 19, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.